Skip to main content
BIOMERICA INC logo

BIOMERICA INC — Investor Relations & Filings

Ticker · BMRA ISIN · US09061H3075 US Manufacturing
Open in API
Filings indexed 587 across all filing types
Latest filing 2023-12-11 Director's Dealing
Country US United States of America
Listing US BMRA

About BIOMERICA INC

https://biomerica.com/

Biomerica, Inc. is a global biomedical technology company that develops, patents, manufactures, and markets advanced in-vitro diagnostic (IVD) and therapeutic products. The company provides solutions for both laboratory and at-home testing, designed for the early detection and monitoring of chronic conditions. Its primary research and development focus is on gastrointestinal and inflammatory diseases, with a notable pipeline that includes a non-drug, diagnostic-guided therapy for Irritable Bowel Syndrome (IBS). Biomerica's products aim to enhance patient health and well-being while contributing to the reduction of total healthcare costs.

Recent filings

Filing Released Lang Actions
Director's Dealing 2023
Director's Dealing
2023-12-11 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Q1 2024
2023-10-12 English
Regulatory Filings 2023
Regulatory Filings
2023-10-02 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The provided document text appears to be heavily encoded or encrypted, containing no readable or meaningful content related to financial reporting, regulatory announcements, or corporate filings. There are no identifiable keywords, regulatory body references, form names, fiscal period dates, or document titles that would allow classification into any specific filing category. Given the lack of discernible information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS). The document length is sufficient to exclude it being a mere announcement or certification, but the content is unintelligible, so it cannot be classified as a substantive report or announcement type.
2023-09-29 English
Capital/Financing Update 2023
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It is a correspondence related to a capital raising filing, not the filing itself. The document is short (1443 characters) and does not contain financial data or report content. It is an update or notice about a financing filing, specifically a request for effectiveness acceleration of a registration statement. Therefore, it fits best under Capital/Financing Update (CAP).
2023-09-29 English
Capital/Financing Update 2023
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by Biomerica, Inc. It is a registration statement under the Securities Act of 1933 used for registering securities for public offering. The text includes details about the offering, prospectus information, risk factors, and legal disclaimers. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement, not just an announcement or a certification, so it is not RPA or RNS. Confidence is high given the clear identification of the form and content.
2023-09-27 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.